首页 > 最新文献

Cancer Epidemiology最新文献

英文 中文
Incident cardiovascular disease risk among older Asian, Native Hawaiian and Pacific Islander liver cancer survivors 亚裔、夏威夷原住民和太平洋岛民老年肝癌幸存者的心血管疾病发病风险。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-02 DOI: 10.1016/j.canep.2024.102680
Jing Wang , Yancen Pan , Chun-Pin Esther Chang , Anees Daud , Randa Tao , Mia Hashibe

Background

Cardiovascular disease (CVD) is a significant global health concern, particularly among Asian, Native Hawaiian, and Pacific Islander (ANHPI) communities that face unique health challenges. Liver cancer disproportionately affects ANHPI populations and has intricate associations with CVD risks due to shared pathophysiological mechanisms and metabolic disturbances. However, the specific CVD risk profile of ANHPI liver cancer patients remains poorly understood.

Methods

Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we identified and matched 1150 ANHPI and 2070 Non-Hispanic White (NHW) liver cancer patients diagnosed between 2000 and 2017. We used the Fine-Gray sub-distribution hazard model to estimate hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) for CVD risks, including ischemic heart disease (IHD), heart failure, and stroke, among ANHPI liver cancer patients compared to NHW counterparts and among ANHPI subgroups.

Results

ANHPI liver cancer patients demonstrated a lower risk of IHD compared to NHW counterparts (HR, 0.65, 95 % CI, 0.50, 0.86), aligning with broader trends. Subgroup analysis revealed notable heterogeneity within ANHPI populations, with Southeast Asian (HR, 0.65, 95 % CI, 0.42, 1.00) and Chinese patients (HR, 0.53, 95 % CI, 0.33–0.83) exhibiting lower IHD risks compared to their NHW counterparts. However, Native Hawaiian and Pacific Islander liver cancer patients showed elevated risks of heart failure (HR, 3.16, 95 % CI, 1.35–7.39) and IHD (HR, 5.64, 95 % CI, 2.19–14.53) compared to their Chinese counterparts.

Conclusion

Our study highlights the complexity of CVD risks among ANHPI liver cancer patients. Addressing these disparities is crucial for improving cardiovascular outcomes and reducing the burden of CVD among ANHPI liver cancer patients.
背景:心血管疾病(CVD)是全球关注的重大健康问题,尤其是在面临独特健康挑战的亚裔、夏威夷原住民和太平洋岛民(ANHPI)群体中。肝癌不成比例地影响着亚裔夏威夷及太平洋岛民群体,由于共同的病理生理机制和代谢紊乱,肝癌与心血管疾病风险有着错综复杂的联系。然而,ANHPI 肝癌患者的具体心血管疾病风险概况仍鲜为人知:我们利用监测、流行病学和最终结果(SEER)-医疗保险数据,确定并匹配了 1150 名 ANHPI 和 2070 名在 2000 年至 2017 年期间确诊的非西班牙裔白人(NHW)肝癌患者。我们使用 Fine-Gray 亚分布危险模型估算了 ANHPI 肝癌患者与 NHW 患者以及 ANHPI 亚组之间的心血管疾病(包括缺血性心脏病 (IHD)、心力衰竭和中风)风险的危险比 (HRs) 和 95 % 置信区间 (95 % CIs):ANHPI肝癌患者的IHD风险低于NHW肝癌患者(HR, 0.65, 95 % CI, 0.50, 0.86),与更广泛的趋势一致。亚组分析显示,ANHPI人群内部存在明显的异质性,东南亚(HR,0.65,95 % CI,0.42,1.00)和中国患者(HR,0.53,95 % CI,0.33-0.83)的IHD风险低于NHW人群。然而,与华裔患者相比,夏威夷原住民和太平洋岛民肝癌患者发生心力衰竭(HR,3.16,95 % CI,1.35-7.39)和IHD(HR,5.64,95 % CI,2.19-14.53)的风险较高:我们的研究强调了ANHPI肝癌患者心血管疾病风险的复杂性。结论:我们的研究凸显了非裔美国人肝癌患者心血管疾病风险的复杂性,解决这些差异对于改善非裔美国人肝癌患者的心血管疾病预后和减轻心血管疾病负担至关重要。
{"title":"Incident cardiovascular disease risk among older Asian, Native Hawaiian and Pacific Islander liver cancer survivors","authors":"Jing Wang ,&nbsp;Yancen Pan ,&nbsp;Chun-Pin Esther Chang ,&nbsp;Anees Daud ,&nbsp;Randa Tao ,&nbsp;Mia Hashibe","doi":"10.1016/j.canep.2024.102680","DOIUrl":"10.1016/j.canep.2024.102680","url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular disease (CVD) is a significant global health concern, particularly among Asian, Native Hawaiian, and Pacific Islander (ANHPI) communities that face unique health challenges. Liver cancer disproportionately affects ANHPI populations and has intricate associations with CVD risks due to shared pathophysiological mechanisms and metabolic disturbances. However, the specific CVD risk profile of ANHPI liver cancer patients remains poorly understood.</div></div><div><h3>Methods</h3><div>Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we identified and matched 1150 ANHPI and 2070 Non-Hispanic White (NHW) liver cancer patients diagnosed between 2000 and 2017. We used the Fine-Gray sub-distribution hazard model to estimate hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) for CVD risks, including ischemic heart disease (IHD), heart failure, and stroke, among ANHPI liver cancer patients compared to NHW counterparts and among ANHPI subgroups.</div></div><div><h3>Results</h3><div>ANHPI liver cancer patients demonstrated a lower risk of IHD compared to NHW counterparts (HR, 0.65, 95 % CI, 0.50, 0.86), aligning with broader trends. Subgroup analysis revealed notable heterogeneity within ANHPI populations, with Southeast Asian (HR, 0.65, 95 % CI, 0.42, 1.00) and Chinese patients (HR, 0.53, 95 % CI, 0.33–0.83) exhibiting lower IHD risks compared to their NHW counterparts. However, Native Hawaiian and Pacific Islander liver cancer patients showed elevated risks of heart failure (HR, 3.16, 95 % CI, 1.35–7.39) and IHD (HR, 5.64, 95 % CI, 2.19–14.53) compared to their Chinese counterparts.</div></div><div><h3>Conclusion</h3><div>Our study highlights the complexity of CVD risks among ANHPI liver cancer patients. Addressing these disparities is crucial for improving cardiovascular outcomes and reducing the burden of CVD among ANHPI liver cancer patients.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102680"},"PeriodicalIF":2.4,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mapping the patient journey and treatment patterns in early-stage (stage I-III) non-small cell lung cancer 绘制早期(I-III 期)非小细胞肺癌患者的病程和治疗模式图。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.1016/j.canep.2024.102678
Sarah Sharman Moser , Shira Yaari , Lior Apter , Bernadette Poellinger , Milan Rheenen , Ashwini Arunachalam , Gabriel Chodick , Moshe Hoshen , Sivan Gazit , Nava Siegelmann-Danieli

Introduction

We map the patient journey from symptom onset to intervention and describe primary treatment in a retrospective population-based cohort study of patients in a large healthcare-provider.

Methods

Newly diagnosed adult patients diagnosed with stages I-III non-small cell lung cancer (NSCLC) between 2016 and 2019 were identified from the Israel National Cancer Registry and chart review was performed to extract de-identified data. The following timelines were constructed: from symptom onset to imaging, imaging to biopsy, and biopsy to primary treatment initiation. Cutoff: 31st December 2021. The initial symptom was captured up to one year prior to biopsy.

Results

Among 302 patients (41 % female, 70 % >=65 years, 79 % former or current smoking, 62 % adenocarcinoma), 34.1 % stage I, 10.3 % stage II, 42.1 % stage III and 13.6 % unknown (AJCC ver. 8). In the baseline year, 80.5 % of patients reported at least one symptom to their physician, and 12.3 % reported four or more symptoms. The most common symptoms reported were cough (29.8 %), pneumonia (24.2 %), chest pain (18.5 %), bronchitis (17.5 %) and wheezing (17.2 %). For patients with an initial symptom (n=243) median time from symptom onset to imaging was 5.5 months (95% CI:4.8–6.3), and time from imaging to primary treatment initiation was 2.6 (2.3–2.9) months in all patients. Total duration from symptom to intervention was 8.5 months (7.6–9.3). Over 93 % of stage I patients underwent surgery and 4.9 % received definitive radiation. Over 83 % of stage II patients underwent surgery; of these, 54.8 % received adjuvant/neoadjuvant chemotherapy. Of stage III patients, 68.5 % received definitive chemoradiation (half received durvalumab), and the remaining underwent surgery with adjuvant/neoadjuvant treatment.

Conclusion

A total of 80.5 % of patients were symptomatic and the median duration from symptom onset to treatment initiation was 8.5 month long. Improving patient and physician awareness to lung cancer symptoms, and the introduction of screening programs are essential for reducing those delays.
简介:我们绘制了大型医疗机构患者从症状出现到接受干预的过程,并描述了主要治疗方法:我们在一项基于人群的回顾性队列研究中绘制了患者从症状出现到接受干预的过程,并描述了一家大型医疗机构对患者的主要治疗方法:从以色列国家癌症登记处确定了2016年至2019年期间新诊断出的I-III期非小细胞肺癌(NSCLC)成人患者,并进行了病历审查以提取去身份化数据。构建了以下时间线:从症状发作到成像,从成像到活检,从活检到开始主要治疗。截止日期:2021 年 12 月 31 日。活组织检查前一年内采集初始症状:在 302 名患者中(41% 为女性,70% 年龄大于等于 65 岁,79% 曾经或正在吸烟,62% 为腺癌),34.1% 为 I 期,10.3% 为 II 期,42.1% 为 III 期,13.6% 为未知期(AJCC 第 8 版)。在基线年,80.5% 的患者向医生报告了至少一种症状,12.3% 的患者报告了四种或更多症状。最常见的症状是咳嗽(29.8%)、肺炎(24.2%)、胸痛(18.5%)、支气管炎(17.5%)和喘息(17.2%)。有初始症状的患者(243 人)从症状出现到成像的中位时间为 5.5 个月(95% CI:4.8-6.3),所有患者从成像到开始初级治疗的时间为 2.6(2.3-2.9)个月。从出现症状到采取干预措施的总时间为 8.5 个月(7.6-9.3 个月)。超过 93% 的 I 期患者接受了手术,4.9% 接受了明确的放射治疗。超过 83% 的 II 期患者接受了手术,其中 54.8% 接受了辅助/新辅助化疗。在III期患者中,68.5%接受了明确的化学放疗(一半接受了杜伐单抗),其余患者接受了手术和辅助/新辅助治疗:结论:80.5%的患者无症状,从出现症状到开始治疗的中位时间为8.5个月。提高患者和医生对肺癌症状的认识以及引入筛查计划对减少这些延误至关重要。
{"title":"Mapping the patient journey and treatment patterns in early-stage (stage I-III) non-small cell lung cancer","authors":"Sarah Sharman Moser ,&nbsp;Shira Yaari ,&nbsp;Lior Apter ,&nbsp;Bernadette Poellinger ,&nbsp;Milan Rheenen ,&nbsp;Ashwini Arunachalam ,&nbsp;Gabriel Chodick ,&nbsp;Moshe Hoshen ,&nbsp;Sivan Gazit ,&nbsp;Nava Siegelmann-Danieli","doi":"10.1016/j.canep.2024.102678","DOIUrl":"10.1016/j.canep.2024.102678","url":null,"abstract":"<div><h3>Introduction</h3><div>We map the patient journey from symptom onset to intervention and describe primary treatment in a retrospective population-based cohort study of patients in a large healthcare-provider.</div></div><div><h3>Methods</h3><div>Newly diagnosed adult patients diagnosed with stages I-III non-small cell lung cancer (NSCLC) between 2016 and 2019 were identified from the Israel National Cancer Registry and chart review was performed to extract de-identified data. The following timelines were constructed: from symptom onset to imaging, imaging to biopsy, and biopsy to primary treatment initiation. Cutoff: 31st December 2021. The initial symptom was captured up to one year prior to biopsy.</div></div><div><h3>Results</h3><div>Among 302 patients (41 % female, 70 % &gt;=65 years, 79 % former or current smoking, 62 % adenocarcinoma), 34.1 % stage I, 10.3 % stage II, 42.1 % stage III and 13.6 % unknown (AJCC ver. 8). In the baseline year, 80.5 % of patients reported at least one symptom to their physician, and 12.3 % reported four or more symptoms. The most common symptoms reported were cough (29.8 %), pneumonia (24.2 %), chest pain (18.5 %), bronchitis (17.5 %) and wheezing (17.2 %). For patients with an initial symptom (n=243) median time from symptom onset to imaging was 5.5 months (95% CI:4.8–6.3), and time from imaging to primary treatment initiation was 2.6 (2.3–2.9) months in all patients. Total duration from symptom to intervention was 8.5 months (7.6–9.3). Over 93 % of stage I patients underwent surgery and 4.9 % received definitive radiation. Over 83 % of stage II patients underwent surgery; of these, 54.8 % received adjuvant/neoadjuvant chemotherapy. Of stage III patients, 68.5 % received definitive chemoradiation (half received durvalumab), and the remaining underwent surgery with adjuvant/neoadjuvant treatment.</div></div><div><h3>Conclusion</h3><div>A total of 80.5 % of patients were symptomatic and the median duration from symptom onset to treatment initiation was 8.5 month long. Improving patient and physician awareness to lung cancer symptoms, and the introduction of screening programs are essential for reducing those delays.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102678"},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Machine learning computational model to predict lung cancer using electronic medical records”. Journal: Cancer Epidemiology, volume 92 (2024) 利用电子病历预测肺癌的机器学习计算模型 "的更正。期刊:癌症流行病学》,第 92 卷(2024 年)。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-09-30 DOI: 10.1016/j.canep.2024.102649
Matanel Levi , Teddy Lazebnik , Shiri Kushnir , Noga Yosef , Dekel Shlomi
{"title":"Corrigendum to “Machine learning computational model to predict lung cancer using electronic medical records”. Journal: Cancer Epidemiology, volume 92 (2024)","authors":"Matanel Levi ,&nbsp;Teddy Lazebnik ,&nbsp;Shiri Kushnir ,&nbsp;Noga Yosef ,&nbsp;Dekel Shlomi","doi":"10.1016/j.canep.2024.102649","DOIUrl":"10.1016/j.canep.2024.102649","url":null,"abstract":"","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102649"},"PeriodicalIF":2.4,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Three-year hospital service use trajectories of people diagnosed with cancer: A retrospective cohort study 确诊癌症患者的三年医院服务使用轨迹:回顾性队列研究
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-09-19 DOI: 10.1016/j.canep.2024.102676
Rebecca J. Mitchell , Geoffrey P. Delaney , Gaston Arnolda , Winston Liauw , Reidar P. Lystad , Jeffrey Braithwaite

Background

Information regarding hospital service use by people newly diagnosed with cancer can inform patterns of healthcare utilisation and resource demands. This study aims to identify characteristics of group-based trajectories of hospital service use three years after an individual was diagnosed with cancer; and determine factors predictive of trajectory group membership.

Method

A group-based trajectory analysis of hospital service use of people aged ≥30 years who had a new diagnosis of cancer during 2018 in New South Wales, Australia was conducted. Linked cancer registry, hospital and mortality data were examined for a three-year period after diagnosis. Group-based trajectory models were derived based on number of hospital admissions. Multinominal logistic regression examined predictors of trajectory group membership.

Results

Of the 44,577 new cancer diagnosis patients, 29,085 (65.2 %) were hospitalised at least once since their cancer diagnosis. Four distinct trajectory groups of hospital users were identified: Low (68.4 %), Very-Low (25.1 %), Moderate-Chronic (2.2 %), and Early-High (4.2 %). Key predictors of trajectory group membership were age group, cancer type, degree of cancer spread, prior history of cancer, receiving chemotherapy, and presence of comorbidities, including renal disease, moderate/serious liver disease, or anxiety.

Conclusions

Comorbidities should be considered in cancer treatment and management decision making. Caring for people diagnosed with cancer with multimorbidity requires multidisciplinary shared care.

背景有关新诊断出癌症的患者使用医院服务的信息可以为医疗保健的使用模式和资源需求提供参考。本研究旨在确定个人被诊断出癌症三年后基于群体的医院服务使用轨迹的特征;并确定预测轨迹群体成员的因素。方法对澳大利亚新南威尔士州2018年期间新诊断出癌症的≥30岁人群的医院服务使用情况进行了基于群体的轨迹分析。对诊断后三年内的关联癌症登记、医院和死亡率数据进行了检查。根据入院人数得出了基于组别的轨迹模型。结果 在 44,577 名新确诊癌症患者中,29,085 人(65.2%)在确诊癌症后至少住院一次。结果发现了四个不同的住院患者轨迹组别:低度组(68.4%)、极低度组(25.1%)、中度慢性组(2.2%)和早期高度组(4.2%)。癌症治疗和管理决策中应考虑合并症。照顾确诊患有多病的癌症患者需要多学科共同护理。
{"title":"Three-year hospital service use trajectories of people diagnosed with cancer: A retrospective cohort study","authors":"Rebecca J. Mitchell ,&nbsp;Geoffrey P. Delaney ,&nbsp;Gaston Arnolda ,&nbsp;Winston Liauw ,&nbsp;Reidar P. Lystad ,&nbsp;Jeffrey Braithwaite","doi":"10.1016/j.canep.2024.102676","DOIUrl":"10.1016/j.canep.2024.102676","url":null,"abstract":"<div><h3>Background</h3><p>Information regarding hospital service use by people newly diagnosed with cancer can inform patterns of healthcare utilisation and resource demands. This study aims to identify characteristics of group-based trajectories of hospital service use three years after an individual was diagnosed with cancer; and determine factors predictive of trajectory group membership.</p></div><div><h3>Method</h3><p>A group-based trajectory analysis of hospital service use of people aged ≥30 years who had a new diagnosis of cancer during 2018 in New South Wales, Australia was conducted. Linked cancer registry, hospital and mortality data were examined for a three-year period after diagnosis. Group-based trajectory models were derived based on number of hospital admissions. Multinominal logistic regression examined predictors of trajectory group membership.</p></div><div><h3>Results</h3><p>Of the 44,577 new cancer diagnosis patients, 29,085 (65.2 %) were hospitalised at least once since their cancer diagnosis. Four distinct trajectory groups of hospital users were identified: Low (68.4 %), Very-Low (25.1 %), Moderate-Chronic (2.2 %), and Early-High (4.2 %). Key predictors of trajectory group membership were age group, cancer type, degree of cancer spread, prior history of cancer, receiving chemotherapy, and presence of comorbidities, including renal disease, moderate/serious liver disease, or anxiety.</p></div><div><h3>Conclusions</h3><p>Comorbidities should be considered in cancer treatment and management decision making. Caring for people diagnosed with cancer with multimorbidity requires multidisciplinary shared care.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102676"},"PeriodicalIF":2.4,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1877782124001553/pdfft?md5=de1638037fdaf88adc27bf8f3758b4c2&pid=1-s2.0-S1877782124001553-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142272237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examining concordance with the guidelines of the national comprehensive cancer network for the treatment of endometrial cancer in Puerto Rico 检查波多黎各子宫内膜癌治疗是否符合国家综合癌症网络的指导方针
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-09-19 DOI: 10.1016/j.canep.2024.102664
Yisel Pagán-Santana , Maira Castañeda-Avila , Ruth Ríos-Motta , Luis Santos-Reyes , Karen J. Ortiz-Ortiz

Background

Endometrial cancer poses a significant health concern in Puerto Rico, where it ranks as the primary gynecological malignancy among women. This study evaluates concordance with the National Comprehensive Cancer Network (NCCN) guidelines for endometrial cancer first treatment in Puerto Rican women and its association with 5-year overall survival.

Methods

Data on patients with endometrial cancer diagnosed between 2009 and 2015 was obtained from the Puerto Rico Central Cancer Registry, which is linked to the Puerto Rico Health Insurance Linkage database (n = 2114). The association between receiving guideline-concordant first treatment and clinical, socioeconomic, and health system factors was evaluated using logistic regression. The 5-year overall survival was calculated using the Kaplan-Meier method. Cox proportional hazard regression models were used to estimate hazard ratios and 95 % confidence intervals (CIs) for associations between guideline-concordant first treatment and overall survival.

Results

In our cohort, 53.9 % of patients received guideline-concordant first treatment. Receiving care at a Commission on Cancer-accredited center, being evaluated by a gynecologist-oncologist, and possessing private insurance enhanced the likelihood of receiving guideline-concordant first treatment. In the Cox regression models, receiving guideline-concordant first treatment was associated with a lower mortality risk (HR: 0.72, 95 % CI: 0.59–0.89).

Conclusion

Guideline-concordant first treatment is a strong predictor of improved survival rates in endometrial cancer. Given that guidelines based on scientific evidence have been demonstrated to enhance patient outcomes, we must understand and promote the factors contributing to their adoption.

背景在波多黎各,子宫内膜癌是女性最主要的妇科恶性肿瘤,对健康构成了严重威胁。本研究评估了波多黎各妇女接受国家综合癌症网络(NCCN)指南规定的子宫内膜癌首次治疗的一致性及其与 5 年总生存率的关系。方法 2009 年至 2015 年期间确诊的子宫内膜癌患者数据来自波多黎各中央癌症登记处,该登记处与波多黎各健康保险链接数据库(n = 2114)相连。采用逻辑回归法评估了接受指南一致的首次治疗与临床、社会经济和医疗系统因素之间的关系。采用 Kaplan-Meier 法计算 5 年总生存率。我们使用 Cox 比例危险回归模型估算了指南一致的首次治疗与总生存率之间的危险比和 95% 的置信区间 (CI)。在癌症委员会认可的中心接受治疗、由妇科肿瘤专家进行评估以及拥有私人保险,这些因素都增加了患者接受与指南一致的首次治疗的可能性。在 Cox 回归模型中,接受与指南一致的首次治疗与较低的死亡风险相关(HR:0.72,95 % CI:0.59-0.89)。鉴于以科学证据为基础的指南已被证明能提高患者的治疗效果,我们必须了解并促进采用这些指南的因素。
{"title":"Examining concordance with the guidelines of the national comprehensive cancer network for the treatment of endometrial cancer in Puerto Rico","authors":"Yisel Pagán-Santana ,&nbsp;Maira Castañeda-Avila ,&nbsp;Ruth Ríos-Motta ,&nbsp;Luis Santos-Reyes ,&nbsp;Karen J. Ortiz-Ortiz","doi":"10.1016/j.canep.2024.102664","DOIUrl":"10.1016/j.canep.2024.102664","url":null,"abstract":"<div><h3>Background</h3><p>Endometrial cancer poses a significant health concern in Puerto Rico, where it ranks as the primary gynecological malignancy among women. This study evaluates concordance with the National Comprehensive Cancer Network (NCCN) guidelines for endometrial cancer first treatment in Puerto Rican women and its association with 5-year overall survival.</p></div><div><h3>Methods</h3><p>Data on patients with endometrial cancer diagnosed between 2009 and 2015 was obtained from the Puerto Rico Central Cancer Registry, which is linked to the Puerto Rico Health Insurance Linkage database (n = 2114). The association between receiving guideline-concordant first treatment and clinical, socioeconomic, and health system factors was evaluated using logistic regression. The 5-year overall survival was calculated using the Kaplan-Meier method. Cox proportional hazard regression models were used to estimate hazard ratios and 95 % confidence intervals (CIs) for associations between guideline-concordant first treatment and overall survival.</p></div><div><h3>Results</h3><p>In our cohort, 53.9 % of patients received guideline-concordant first treatment. Receiving care at a Commission on Cancer-accredited center, being evaluated by a gynecologist-oncologist, and possessing private insurance enhanced the likelihood of receiving guideline-concordant first treatment. In the Cox regression models, receiving guideline-concordant first treatment was associated with a lower mortality risk (HR: 0.72, 95 % CI: 0.59–0.89).</p></div><div><h3>Conclusion</h3><p>Guideline-concordant first treatment is a strong predictor of improved survival rates in endometrial cancer. Given that guidelines based on scientific evidence have been demonstrated to enhance patient outcomes, we must understand and promote the factors contributing to their adoption.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102664"},"PeriodicalIF":2.4,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1877782124001437/pdfft?md5=deae112d0a660451373178400ea6a6e4&pid=1-s2.0-S1877782124001437-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142241589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Colorectal cancer in older adults after the USPSTF’s 2008 updated screening recommendation USPSTF 2008 年更新筛查建议后的老年人结直肠癌情况
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-09-18 DOI: 10.1016/j.canep.2024.102677
Jason Semprini

Background

Colorectal cancer (CRC) screenings can improve detection and prevent precancerous polyps from becoming malignant tumors. In 2008, the United States Preventive Services Task Force (USPSTF) updated their policy and no longer recommended that adults over age 75 screen for CRC. We evaluated how this policy update impacted screening behaviors and CRC outcomes in older adults.

Methods

We obtained data from the Behavioral Risk Factor Surveillance System to analyze blood stool and colonoscopy screening, the Surveillance, Epidemiological, End Results program to analyze CRC staging and survival, the National Association of Centralized Cancer Registries to analyze CRC incidence, and the National Center for Health Statistics to analyze mortality. With a difference-in-differences design, we compared the changes in outcome trends of the exposed group (age 75+), before and after 2008, with the changes in trends of a similar unexposed group (age 65–74).

Results

There was no association between the 2008 update and blood stool tests in older adults. We did, however, find that the update was associated with a 3.0 %-point decline in the probability of older adults completing a colonoscopy within the past two years (C.I. = −4.0, −2.0). Among older adults diagnosed with CRC, the update was associated with a 1.5 %-point increase in the probability of presenting at an advanced stage (C.I. = 1.1, 1.9). Finally, the update was also associated with lower CRC incidence (Est. = −13.9 cases/100,000 population; C.I. = −22.6, −5.1) and mortality rates (Est. = −5.6 deaths/100,000 population; C.I. = −10.1, −1.1). We observed the largest associations between the policy and CRC outcomes in adults age 85+.

Discussion

The USPSTF’s 2008 recommendation was associated with reduced colonoscopies, especially in adults over age 85. Whether this recommendation, or the 2021 updated guidance, optimizes population health by reducing the burden of CRC screening in older adults remains unknown.

背景直肠癌(CRC)筛查可以提高发现率,防止癌前息肉变成恶性肿瘤。2008 年,美国预防服务工作组(USPSTF)更新了他们的政策,不再建议 75 岁以上的成年人进行 CRC 筛查。我们从行为风险因素监测系统(Behavioral Risk Factor Surveillance System)获取数据,分析血便和结肠镜筛查情况;从监测、流行病学和最终结果项目(Surveillance, Epidemiological, End Results program)获取数据,分析 CRC 分期和存活情况;从全国癌症集中登记协会(National Association of Centralized Cancer Registries)获取数据,分析 CRC 发病率;从全国卫生统计中心(National Center for Health Statistics)获取数据,分析死亡率。通过差分设计,我们比较了 2008 年前后暴露组(75 岁以上)与类似的未暴露组(65-74 岁)的结果趋势变化。但我们发现,2008 年的更新与老年人在过去两年内完成结肠镜检查的概率下降 3.0% 个百分点有关(C.I. = -4.0, -2.0)。在确诊为 CRC 的老年人中,更新后出现晚期的概率增加了 1.5 个百分点(C.I. = 1.1, 1.9)。最后,政策更新还与较低的 CRC 发病率(估计值 = -13.9 例/100,000 人口;C.I. = -22.6, -5.1)和死亡率(估计值 = -5.6 例死亡/100,000 人口;C.I. = -10.1, -1.1)相关。讨论USPSTF 2008 年的建议与结肠镜检查次数减少有关,尤其是在 85 岁以上的成年人中。该建议或 2021 年更新的指南是否能通过减轻老年人的 CRC 筛查负担来优化人口健康仍是未知数。
{"title":"Colorectal cancer in older adults after the USPSTF’s 2008 updated screening recommendation","authors":"Jason Semprini","doi":"10.1016/j.canep.2024.102677","DOIUrl":"10.1016/j.canep.2024.102677","url":null,"abstract":"<div><h3>Background</h3><p>Colorectal cancer (CRC) screenings can improve detection and prevent precancerous polyps from becoming malignant tumors. In 2008, the United States Preventive Services Task Force (USPSTF) updated their policy and no longer recommended that adults over age 75 screen for CRC. We evaluated how this policy update impacted screening behaviors and CRC outcomes in older adults.</p></div><div><h3>Methods</h3><p>We obtained data from the Behavioral Risk Factor Surveillance System to analyze blood stool and colonoscopy screening, the Surveillance, Epidemiological, End Results program to analyze CRC staging and survival, the National Association of Centralized Cancer Registries to analyze CRC incidence, and the National Center for Health Statistics to analyze mortality. With a difference-in-differences design, we compared the changes in outcome trends of the exposed group (age 75+), before and after 2008, with the changes in trends of a similar unexposed group (age 65–74).</p></div><div><h3>Results</h3><p>There was no association between the 2008 update and blood stool tests in older adults. We did, however, find that the update was associated with a 3.0 %-point decline in the probability of older adults completing a colonoscopy within the past two years (C.I. = −4.0, −2.0). Among older adults diagnosed with CRC, the update was associated with a 1.5 %-point increase in the probability of presenting at an advanced stage (C.I. = 1.1, 1.9). Finally, the update was also associated with lower CRC incidence (Est. = −13.9 cases/100,000 population; C.I. = −22.6, −5.1) and mortality rates (Est. = −5.6 deaths/100,000 population; C.I. = −10.1, −1.1). We observed the largest associations between the policy and CRC outcomes in adults age 85+.</p></div><div><h3>Discussion</h3><p>The USPSTF’s 2008 recommendation was associated with reduced colonoscopies, especially in adults over age 85. Whether this recommendation, or the 2021 updated guidance, optimizes population health by reducing the burden of CRC screening in older adults remains unknown.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102677"},"PeriodicalIF":2.4,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142241838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trajectories in mammographic breast screening participation in middle-age overweight and obese women: A retrospective cohort study using linked data 中年超重和肥胖妇女参与乳腺 X 线照相筛查的轨迹:使用关联数据的回顾性队列研究
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-09-17 DOI: 10.1016/j.canep.2024.102675
K.A. McBride , S. Munasinghe , S. Sperandei , A.N. Page

Objectives

Despite the established benefits and availability of mammographic breast screening, participation rates remain suboptimal. Women with higher BMIs may not screen regularly, despite being at increased risk of postmenopausal breast cancer and worse outcomes. This study investigated the association between prospective changes in BMI and longitudinal adherence to mammographic screening among women with overweight or obesity.

Methods

Retrospective cohort study of women (N = 2822) participating in the Australian Longitudinal Study on Women's Health with an average follow-up of 20 years, with screening participation enumerated via BreastScreen NSW, Australia clinical records over the period 1996–2016. Association between BMI and subsequent adherence to screening was investigated in a series of marginal structural models, incorporating a time variant/invariant socio-demographic, clinical, and health behaviour confounders. Models were also stratified by a proxy measure of socio-economic status (education).

Results

Participants with overweight/obesity were less adherent to mammography screening, compared to healthy/underweight participants (OR=1.29, 95 % CI=1.07, 1.55). The association between overweight/obesity and non-adherence was higher among those who ever had private health insurance (OR=1.30, 95 % CI=1.05, 1.61) compared to those who never had private health insurance and among those with lower educational background (OR=1.38, 95 % CI=1.08, 1.75) compared to those with higher educational background.

Conclusions

Long-term impacts on screening participation exist among women with higher BMI, who are less likely to participate in routinely organised breast screening. Women with a higher BMI should be a focus of efforts to improve breast screening participation, particularly given their increased risk of breast cancer and association of higher BMI with worse breast cancer outcomes among older women.

目标尽管乳腺 X 线照相术乳腺筛查具有公认的益处,而且也很普及,但参与率仍然不理想。体重指数(BMI)较高的女性可能不会定期进行筛查,尽管她们绝经后罹患乳腺癌的风险会增加,而且结果也会恶化。本研究调查了超重或肥胖妇女的体重指数前瞻性变化与纵向坚持乳腺X线摄影筛查之间的关系。方法对参加澳大利亚妇女健康纵向研究的妇女(N = 2822)进行回顾性队列研究,平均随访 20 年,通过 1996-2016 年期间澳大利亚新南威尔士州乳腺筛查临床记录统计筛查参与情况。通过一系列边际结构模型研究了体重指数与后续筛查依从性之间的关系,并纳入了时间变量/不变的社会人口学、临床和健康行为混杂因素。结果与健康/体重不足的参与者相比,超重/肥胖的参与者较少坚持乳腺X光筛查(OR=1.29,95 % CI=1.07,1.55)。与从未购买过私人医疗保险的人相比,曾经购买过私人医疗保险的人(OR=1.30,95 % CI=1.05,1.61)和教育背景较低的人(OR=1.38,95 % CI=1.08,1.75)与教育背景较高的人相比,超重/肥胖与不坚持筛查之间的关联度更高。体重指数较高的妇女应成为提高乳腺筛查参与率的重点人群,特别是考虑到她们罹患乳腺癌的风险增加,以及体重指数较高与老年妇女乳腺癌预后较差之间的关联。
{"title":"Trajectories in mammographic breast screening participation in middle-age overweight and obese women: A retrospective cohort study using linked data","authors":"K.A. McBride ,&nbsp;S. Munasinghe ,&nbsp;S. Sperandei ,&nbsp;A.N. Page","doi":"10.1016/j.canep.2024.102675","DOIUrl":"10.1016/j.canep.2024.102675","url":null,"abstract":"<div><h3>Objectives</h3><p>Despite the established benefits and availability of mammographic breast screening, participation rates remain suboptimal. Women with higher BMIs may not screen regularly, despite being at increased risk of postmenopausal breast cancer and worse outcomes. This study investigated the association between prospective changes in BMI and longitudinal adherence to mammographic screening among women with overweight or obesity.</p></div><div><h3>Methods</h3><p>Retrospective cohort study of women (N = 2822) participating in the Australian Longitudinal Study on Women's Health with an average follow-up of 20 years, with screening participation enumerated via BreastScreen NSW, Australia clinical records over the period 1996–2016. Association between BMI and subsequent adherence to screening was investigated in a series of marginal structural models, incorporating a time variant/invariant socio-demographic, clinical, and health behaviour confounders. Models were also stratified by a proxy measure of socio-economic status (education).</p></div><div><h3>Results</h3><p>Participants with overweight/obesity were less adherent to mammography screening, compared to healthy/underweight participants (OR=1.29, 95 % CI=1.07, 1.55). The association between overweight/obesity and non-adherence was higher among those who ever had private health insurance (OR=1.30, 95 % CI=1.05, 1.61) compared to those who never had private health insurance and among those with lower educational background (OR=1.38, 95 % CI=1.08, 1.75) compared to those with higher educational background.</p></div><div><h3>Conclusions</h3><p>Long-term impacts on screening participation exist among women with higher BMI, who are less likely to participate in routinely organised breast screening. Women with a higher BMI should be a focus of efforts to improve breast screening participation, particularly given their increased risk of breast cancer and association of higher BMI with worse breast cancer outcomes among older women.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102675"},"PeriodicalIF":2.4,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1877782124001541/pdfft?md5=f8b1091f2cc80cf82887740fab46530d&pid=1-s2.0-S1877782124001541-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142241588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cervical cancer screening outcomes among First Nations and non‐First Nations women in Alberta, Canada 加拿大艾伯塔省原住民和非原住民妇女的宫颈癌筛查结果
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-09-13 DOI: 10.1016/j.canep.2024.102672
Huiming Yang , Angeline Letendre , Melissa Shea-Budgell , Lea Bill , Bonnie A. Healy , Brittany Shewchuk , Gregg Nelson , James Newsome , Bonnie Chiang , Chinmoy Roy Rahul , Karen A. Kopciuk

Background

Cervical cancer disproportionately affects First Nations women in Canada but there is limited information on their participation in organized cervical cancer screening programs.

Methods

This co-led retrospective cohort study linked population-based Alberta Cervical Cancer Screening Program point of care data with First Nations identifiers. This Screening Program database includes cervical cancer screening history, screen test results, colposcopy procedure findings, and pathology results for all women in Alberta. First Nations identifiers were obtained from Alberta Health who steward these data on their behalf. Data were available from 2012 to 2018 for women 25 – 69 years of age who were age eligible to participate in cervical cancer screening. Screening participation and retention rates, and screening outcomes were compared between First Nations and non- First Nations women using descriptive statistics with trends estimated using joinpoint models.

Results

Age standardized screening participation and retention rates of First Nations women were lower than those for the non-First Nations women, with an average difference of 13.9 % lower for participation rates (95 % confidence interval = 12.9–14.8 %; P <.0001) and 7.2 % for retention rates (95 % confidence interval = 2.2 % to 12.72; P = 0.013). First Nations women consistently had higher percentages of high risk (high-grade squamous intraepithelial lesion, atypical glandular cells, atypical squamous cells where HSIL cannot be excluded, Carcinoma in situ) abnormal cytology tests than non-First Nations women.

Conclusion

Identifying where inequities were found in cervical cancer screening participation and retention in this study is the first step to reduce the disproportionate burden of cervical cancer for First Nations women in Canada.

这项共同领导的回顾性队列研究将基于人口的艾伯塔省宫颈癌筛查计划护理点数据与原住民身份识别信息联系起来。该筛查计划数据库包括艾伯塔省所有妇女的宫颈癌筛查史、筛查测试结果、阴道镜检查结果和病理结果。阿尔伯塔省卫生厅代表原住民管理这些数据,原住民的身份识别信息来自阿尔伯塔省卫生厅。2012 年至 2018 年期间,符合参加宫颈癌筛查年龄条件的 25 岁至 69 岁女性的数据可供使用。结果原住民妇女的年龄标准化筛查参与率和保留率低于非原住民妇女,参与率平均低13.9%(95%置信区间=12.9%-14.8%;P<.0001),保留率平均低7.2%(95%置信区间=2.2%-12.72;P=0.013)。与非原住民妇女相比,原住民妇女的高风险(高级别鳞状上皮内病变、非典型腺细胞、不能排除 HSIL 的非典型鳞状细胞、原位癌)异常细胞学检测比例一直较高。
{"title":"Cervical cancer screening outcomes among First Nations and non‐First Nations women in Alberta, Canada","authors":"Huiming Yang ,&nbsp;Angeline Letendre ,&nbsp;Melissa Shea-Budgell ,&nbsp;Lea Bill ,&nbsp;Bonnie A. Healy ,&nbsp;Brittany Shewchuk ,&nbsp;Gregg Nelson ,&nbsp;James Newsome ,&nbsp;Bonnie Chiang ,&nbsp;Chinmoy Roy Rahul ,&nbsp;Karen A. Kopciuk","doi":"10.1016/j.canep.2024.102672","DOIUrl":"10.1016/j.canep.2024.102672","url":null,"abstract":"<div><h3>Background</h3><p>Cervical cancer disproportionately affects First Nations women in Canada but there is limited information on their participation in organized cervical cancer screening programs.</p></div><div><h3>Methods</h3><p>This co-led retrospective cohort study linked population-based Alberta Cervical Cancer Screening Program point of care data with First Nations identifiers. This Screening Program database includes cervical cancer screening history, screen test results, colposcopy procedure findings, and pathology results for all women in Alberta. First Nations identifiers were obtained from Alberta Health who steward these data on their behalf. Data were available from 2012 to 2018 for women 25 – 69 years of age who were age eligible to participate in cervical cancer screening. Screening participation and retention rates, and screening outcomes were compared between First Nations and non- First Nations women using descriptive statistics with trends estimated using joinpoint models.</p></div><div><h3>Results</h3><p>Age standardized screening participation and retention rates of First Nations women were lower than those for the non-First Nations women, with an average difference of 13.9 % lower for participation rates (95 % confidence interval = 12.9–14.8 %; <em>P</em> &lt;.0001) and 7.2 % for retention rates (95 % confidence interval = 2.2 % to 12.72; <em>P</em> = 0.013). First Nations women consistently had higher percentages of high risk (high-grade squamous intraepithelial lesion, atypical glandular cells, atypical squamous cells where HSIL cannot be excluded, Carcinoma in situ) abnormal cytology tests than non-First Nations women.</p></div><div><h3>Conclusion</h3><p>Identifying where inequities were found in cervical cancer screening participation and retention in this study is the first step to reduce the disproportionate burden of cervical cancer for First Nations women in Canada.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102672"},"PeriodicalIF":2.4,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1877782124001516/pdfft?md5=33a2075b4e95ac46f9ca3c49f73949e8&pid=1-s2.0-S1877782124001516-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spatial and temporal analysis of breast cancer mortality in a state in northeastern Brazil 巴西东北部一个州乳腺癌死亡率的时空分析
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-09-12 DOI: 10.1016/j.canep.2024.102661
Adriane Dórea Marques , Alex Rodrigues Moura , Brenda Evelin Barreto da Silva , Taiana Resende Silva , Caio Nemuel Nascimento Santos , Lucas Nascimento Severo , Angela Maria da Silva , Carlos Anselmo Lima

Breast cancer (BC) is the most common neoplasm, and its global burden has become one of the most important factors jeopardizing the health of the world population, especially women. The aim of this study was to analyze mortality trends and the spatial distribution of BC in women in the capital and state of Sergipe, aiming to contribute to the implementation and improvement of strategies for the prevention and health promotion of women with BC. Trends were calculated using the Joinpoint Regression Program 5.0.2. Spatial analyses were performed using the empirical Bayesian model, thematic maps were created using QGIS 3.10.7 and Moran's I indices were calculated using TerraView 4.2.2. Between 1996 and 2022, 1384 and 3128 BC deaths were recorded in the capital and state of Sergipe, respectively. The mortality trend increased in the age groups of 45–75+ for the state of Sergipe, while in the capital, we observed stability in all age groups. The highest AAPC was 4.6213, with a 95 % confidence interval (2.16; 7.14). Univariate global Moran's I analysis indicated spatial autocorrelation during the study period. A direct relationship was found between mortality rates and the more economically developed regions.

乳腺癌(BC)是最常见的肿瘤,其全球负担已成为危害世界人口(尤其是妇女)健康的最重要因素之一。本研究的目的是分析塞尔希培州首府妇女乳腺癌的死亡率趋势和空间分布情况,旨在帮助实施和改进预防和促进妇女乳腺癌健康的战略。趋势的计算使用了 Joinpoint Regression Program 5.0.2。使用经验贝叶斯模型进行空间分析,使用 QGIS 3.10.7 绘制专题地图,使用 TerraView 4.2.2 计算莫兰 I 指数。1996 年至 2022 年期间,塞尔希培首府和各州分别记录了 1384 例和 3128 例公元前死亡病例。在塞尔希培州,45-75 岁以上年龄组的死亡率呈上升趋势,而在首府,我们观察到所有年龄组的死亡率均保持稳定。最高AAPC为4.6213,置信区间为95%(2.16;7.14)。单变量全局莫兰 I 分析表明,研究期间存在空间自相关性。死亡率与经济较发达地区之间存在直接关系。
{"title":"Spatial and temporal analysis of breast cancer mortality in a state in northeastern Brazil","authors":"Adriane Dórea Marques ,&nbsp;Alex Rodrigues Moura ,&nbsp;Brenda Evelin Barreto da Silva ,&nbsp;Taiana Resende Silva ,&nbsp;Caio Nemuel Nascimento Santos ,&nbsp;Lucas Nascimento Severo ,&nbsp;Angela Maria da Silva ,&nbsp;Carlos Anselmo Lima","doi":"10.1016/j.canep.2024.102661","DOIUrl":"10.1016/j.canep.2024.102661","url":null,"abstract":"<div><p>Breast cancer (BC) is the most common neoplasm, and its global burden has become one of the most important factors jeopardizing the health of the world population, especially women. The aim of this study was to analyze mortality trends and the spatial distribution of BC in women in the capital and state of Sergipe, aiming to contribute to the implementation and improvement of strategies for the prevention and health promotion of women with BC. Trends were calculated using the Joinpoint Regression Program 5.0.2. Spatial analyses were performed using the empirical Bayesian model, thematic maps were created using QGIS 3.10.7 and Moran's I indices were calculated using TerraView 4.2.2. Between 1996 and 2022, 1384 and 3128 BC deaths were recorded in the capital and state of Sergipe, respectively. The mortality trend increased in the age groups of 45–75+ for the state of Sergipe, while in the capital, we observed stability in all age groups. The highest AAPC was 4.6213, with a 95 % confidence interval (2.16; 7.14). Univariate global Moran's I analysis indicated spatial autocorrelation during the study period. A direct relationship was found between mortality rates and the more economically developed regions.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102661"},"PeriodicalIF":2.4,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142171875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The PROPr can be measured using different PROMIS domain item sets PROPr 可使用不同的 PROMIS 领域项目集进行测量
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-09-10 DOI: 10.1016/j.canep.2024.102658
Christoph Paul Klapproth , Felix Fischer , Annika Doehmen , Milan Kock , Jens Rohde , Kathrin Rieger , Ullrich Keilholz , Matthias Rose , Alexander Obbarius

Background

The Patient-Reported Outcomes Measurement Information System (PROMIS) Preference Score (PROPr) is estimated from descriptive health assessments within the PROMIS framework. The underlying item response theory (IRT) allows researchers to measure PROMIS health domains with any subset of items that are calibrated to this domain. Consequently, this should also be true for the PROPr. We aimed to test this assumption using both an empirical and a simulation approach.

Methods

Empirically, we estimated 3 PROMIS Pain inference (PI) scores from 3 different item subsets in a sample of n=199 cancer patients: 4 PROMIS-29 items (estimate: θ4), the 2 original PROPr items (θ2), and 10 different items (θ10). We calculated mean differences and agreement between θ4, and θ2 and θ10, respectively, and between their resulting PROPr4, PROPr2, PROPr10, using intraclass correlation coefficients (ICC) and Bland-Altman (B-A) plots with 95 %-Limits of Agreement (LoA). For the simulation, we used the IRT-model to calculate all item responses of the entire 7 PROPr domain item banks from the empirically observed PROMIS-29+cognition θ. From these simulated item banks, we chose the 2 original PROPr items per domain to calculate PROPrsim and compared it to PROPr4 again using ICC and B-A plots.

Results

θ4 vs θ10 showed smaller bias (-0.012, 95 %-LoA −0.88;0.85) than θ4 vs θ2 (0.025, 95 %-LoA −0.95;1.00. ICC>0.85 (p<0.001) in both θ-comparisons. PROPr4 vs PROPr10 showed lower bias (0.0012, 95 %-LoA −0.039;0.042) than PROPr4 vs PROPr2 (-0.0029, 95 %-LoA −0.049;0.044). ICC>0.98 (p<0.0001) on both PROPr-comparisons. Mean PROPrsim was larger than mean PROPr4 (0.0228, 95 %-LoA −0.1103; 0.1558) and ICC was 0.95 (95 %CI 0.93; 0.97).

Conclusion

Different item subsets can be used to estimate the PROMIS PI for calculation of the PROPr. Reduction to 2 items per domain rather than 4 does not significantly change the PROPr estimate on average. Agreements differ across the spectrum and in individual comparisons.

背景患者报告结果测量信息系统(PROMIS)偏好分数(PROPr)是在 PROMIS 框架内通过描述性健康评估估算出来的。所依据的项目反应理论(IRT)允许研究人员使用校准到该领域的任何项目子集来测量 PROMIS 健康领域。因此,PROPr 也应如此。我们的目标是使用经验和模拟方法来验证这一假设。方法在经验方面,我们从 3 个不同的项目子集中估算出了 3 个 PROMIS 疼痛推断 (PI) 分数,样本为 n=199 癌症患者:4 个 PROMIS-29 项目(估计值:θ4)、2 个原始 PROPr 项目(θ2)和 10 个不同项目(θ10)。我们使用类内相关系数 (ICC) 和带有 95 % 协议限值 (LoA) 的 Bland-Altman (B-A) 图分别计算了θ4、θ2 和θ10 之间的平均差异和一致性,以及它们所产生的 PROPr4、PROPr2 和 PROPr10 之间的平均差异和一致性。在模拟过程中,我们使用 IRT 模型,根据经验观察到的 PROMIS-29+cognition θ 计算整个 7 个 PROPr 领域项目库的所有项目反应。结果θ4 vs θ10显示的偏差(-0.012,95 %-LoA -0.88;0.85)小于θ4 vs θ2(0.025,95 %-LoA -0.95;1.00)。两个 θ 比较的 ICC>0.85 (p<0.001)。PROPr4 与 PROPr10 的偏差(0.0012,95%-LoA -0.039;0.042)低于 PROPr4 与 PROPr2 的偏差(-0.0029,95%-LoA -0.049;0.044)。两个 PROPr 比较的 ICC>0.98 (p<0.0001)。平均 PROPrsim 大于平均 PROPr4 (0.0228, 95 %-LoA -0.1103; 0.1558),ICC 为 0.95 (95 %CI 0.93; 0.97)。将每个领域的项目从 4 个减少到 2 个并不会明显改变 PROPr 的平均估计值。在不同领域和个别比较中的一致性有所不同。
{"title":"The PROPr can be measured using different PROMIS domain item sets","authors":"Christoph Paul Klapproth ,&nbsp;Felix Fischer ,&nbsp;Annika Doehmen ,&nbsp;Milan Kock ,&nbsp;Jens Rohde ,&nbsp;Kathrin Rieger ,&nbsp;Ullrich Keilholz ,&nbsp;Matthias Rose ,&nbsp;Alexander Obbarius","doi":"10.1016/j.canep.2024.102658","DOIUrl":"10.1016/j.canep.2024.102658","url":null,"abstract":"<div><h3>Background</h3><p>The Patient-Reported Outcomes Measurement Information System (PROMIS) Preference Score (PROPr) is estimated from descriptive health assessments within the PROMIS framework. The underlying item response theory (IRT) allows researchers to measure PROMIS health domains with any subset of items that are calibrated to this domain. Consequently, this should also be true for the PROPr. We aimed to test this assumption using both an empirical and a simulation approach.</p></div><div><h3>Methods</h3><p>Empirically, we estimated 3 PROMIS Pain inference (PI) scores from 3 different item subsets in a sample of n=199 cancer patients: 4 PROMIS-29 items (estimate: θ<sub>4</sub>), the 2 original PROPr items (θ<sub>2</sub>), and 10 different items (θ<sub>10</sub>). We calculated mean differences and agreement between θ<sub>4</sub>, and θ<sub>2</sub> and θ<sub>10</sub>, respectively, and between their resulting PROPr<sub>4</sub>, PROPr<sub>2</sub>, PROPr<sub>10</sub>, using intraclass correlation coefficients (ICC) and Bland-Altman (B-A) plots with 95 %-Limits of Agreement (LoA). For the simulation, we used the IRT-model to calculate all item responses of the entire 7 PROPr domain item banks from the empirically observed PROMIS-29+cognition θ. From these simulated item banks, we chose the 2 original PROPr items per domain to calculate PROPr<sub>sim</sub> and compared it to PROPr<sub>4</sub> again using ICC and B-A plots.</p></div><div><h3>Results</h3><p>θ<sub>4</sub> vs θ<sub>10</sub> showed smaller bias (-0.012, 95 %-LoA −0.88;0.85) than θ<sub>4</sub> vs θ<sub>2</sub> (0.025, 95 %-LoA −0.95;1.00. ICC&gt;0.85 (p&lt;0.001) in both θ-comparisons. PROPr<sub>4</sub> vs PROPr<sub>10</sub> showed lower bias (0.0012, 95 %-LoA −0.039;0.042) than PROPr<sub>4</sub> vs PROPr<sub>2</sub> (-0.0029, 95 %-LoA −0.049;0.044). ICC&gt;0.98 (p&lt;0.0001) on both PROPr-comparisons. Mean PROPr<sub>sim</sub> was larger than mean PROPr<sub>4</sub> (0.0228, 95 %-LoA −0.1103; 0.1558) and ICC was 0.95 (95 %CI 0.93; 0.97).</p></div><div><h3>Conclusion</h3><p>Different item subsets can be used to estimate the PROMIS PI for calculation of the PROPr. Reduction to 2 items per domain rather than 4 does not significantly change the PROPr estimate on average. Agreements differ across the spectrum and in individual comparisons.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102658"},"PeriodicalIF":2.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1877782124001371/pdfft?md5=ce62914936b18250df9ea55f5e9b1419&pid=1-s2.0-S1877782124001371-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142164552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Epidemiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1